KEYNOTE-028 Trial Unveils Biomarkers Linked to Pembrolizumab Efficacy
The results of the study add to the growing body of literature regarding potential biomarkers for response to immune checkpoint inhibitors. (Source: Cancer Network)
Source: Cancer Network - January 16, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

New Second-Line Option for Advanced Gastric Cancer
The results of a phase III randomized trial found that the anti-angiogenesis antibody ramucirumab improved survival in advanced, previously treated gastric cancer. (Source: Cancer Network)
Source: Cancer Network - October 9, 2013 Category: Cancer & Oncology Source Type: news

ECC: Ipilimumab Provides 10-Year Survival in Some Melanoma Patients
Patients with advanced melanoma treated with ipilimumab may be able to survive up to 10 years, according to the results of a study presented at the 2013 European Cancer Congress. (Source: Cancer Network)
Source: Cancer Network - October 8, 2013 Category: Cancer & Oncology Source Type: news

ECC: Everolimus Effective in Advanced Papillary Renal Cell Carcinoma
The mTOR inhibitor everolimus showed clinical efficacy for the initial treatment of advanced papillary renal cell carcinoma, according to the phase II results of the RAPTOR trial. (Source: Cancer Network)
Source: Cancer Network - October 8, 2013 Category: Cancer & Oncology Source Type: news

Tracking Nausea/Vomiting in Diary Helped Health Care Team Reduce Symptoms
Asking patients to track their nausea and vomiting after a course of chemotherapy helped the health care team to adjust medications and achieve better control of symptoms, according to the results of a small single center study. (Source: Cancer Network)
Source: Cancer Network - October 7, 2013 Category: Cancer & Oncology Source Type: news

ECC: T-DM1 May Be New Standard of Care in Heavily Pretreated Advanced Breast Cancer
T-DM1, a combination drug of trastuzumab and a cell-killing drug emtansine, significantly improved progression-free survival in women with advanced HER2-positive breast cancer whose cancer has recurred or progressed despite previous treatments, according to the results of the TH3RESA trial. (Source: Cancer Network)
Source: Cancer Network - October 4, 2013 Category: Cancer & Oncology Source Type: news

Role of BRAF in Papillary Thyroid Carcinoma Still Unclear
A new study of the relationship between BRAF V600E mutation status and its effect on papillary thyroid carcinoma found a negative association with clinicopathologic features suggestive of more aggressive disease. (Source: Cancer Network)
Source: Cancer Network - October 4, 2013 Category: Cancer & Oncology Source Type: news

ECCO 2013: Diabetes Increased Risk for Developing, Dying from Breast or Colon Cancer
A new meta-analysis indicated that people with diabetes are not only at an increased risk of developing breast and colon cancer, but are also at an increased risk of dying from the diseases. (Source: Cancer Network)
Source: Cancer Network - October 4, 2013 Category: Cancer & Oncology Source Type: news

Antidepressants Could Treat Small-Cell Lung Cancer
Researchers used an unbiased bioinformatics approach to identify a class of drugs currently used for non-cancer treatment that could be used to treat small-cell lung cancer, a cancer type for which there are few treatment options. (Source: Cancer Network)
Source: Cancer Network - October 3, 2013 Category: Cancer & Oncology Source Type: news

ECC: Diabetes Increased Risk for Developing, Dying from Breast or Colon Cancer
A new meta-analysis indicated that people with diabetes are not only at an increased risk of developing breast and colon cancer, but are also at an increased risk of dying from the diseases. (Source: Cancer Network)
Source: Cancer Network - October 3, 2013 Category: Cancer & Oncology Source Type: news

Dose-Dense Anthracycline Safe With Anti-HER2 Drugs
Long-term safety and efficacy results of two phase II trials indicate that dose-dense anthracycline-based chemotherapy with doxorubicin and cyclophosphamide can be safely combined with anti-HER2 therapy in women with early breast cancer. (Source: Cancer Network)
Source: Cancer Network - October 3, 2013 Category: Cancer & Oncology Source Type: news

Anti-depressants Could Treat Small-Cell Lung Cancer
Researchers used an unbiased bioinformatics approach to identify a class of drugs currently used for non-cancer treatment that could be used to treat small-cell lung cancer, a cancer type for which there are few treatment options. (Source: Cancer Network)
Source: Cancer Network - October 3, 2013 Category: Cancer & Oncology Source Type: news

ECC: Hyperfractionated Radiotherapy Improved Survival for Head and Neck Cancers
The use of altered fractionation radiotherapy increased overall survival in patients with locally advanced head and neck cancers when compared with standard radiation, according to the results of a meta-analysis presented on Saturday at the 2013 European Cancer Congress in Amsterdam. (Source: Cancer Network)
Source: Cancer Network - October 2, 2013 Category: Cancer & Oncology Source Type: news

Comprehensive Map Shows Role of Viruses Among 19 Cancers
Taking advantage of the copious amounts of data generated from The Cancer Genome Atlas (TCGA), researchers have created a comprehensive map of the viruses present in a wide range of cancer types. (Source: Cancer Network)
Source: Cancer Network - October 2, 2013 Category: Cancer & Oncology Source Type: news

Denosumab Most Effective in High-Risk Prostate Cancer Patients
The anti-RANKL antibody denosumab is more effective for preventing bone metastasis in men with high-risk castration-resistant prostate cancer compared with low-risk disease, according to results of a new study. (Source: Cancer Network)
Source: Cancer Network - October 2, 2013 Category: Cancer & Oncology Source Type: news